EndoResFellow said:They are two different exemptions from the same federal requirements and they buy different things.
Thank you — that is the clearest version of this I have read, and I have read a lot of them.
Clinical perspective, offered as context rather than as advice.
Compounded has been just as effective for me. If compounded supply is the concern, the COA from my 503B pharmacy shows 99.1% purity. Verified by Janoshik.
Dr.SurgeonPGH said:Compounded semaglutide formulations for compounded supply: some pharmacies add ingredients like B12, L-carnitine, or BPC-157 to their semaglutide…
Price comparison for compounded supply across sources I've used:
| Source | Monthly Cost | Type | Purity Verified |
|---|---|---|---|
| Brand (Ozempic) | $1073 | FDA-approved | N/A (pharma) |
| 503B Compounding | $153 | cGMP compounded | Yes (in-house) |
| 503A Compounding | $103 | Patient-specific | Varies |
| Research peptide | $63 | Not for human use | Often Janoshik |
I use the 503B option — best balance of quality, cost, and legality. The brand price is insane but insurance can help if you qualify.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsMeganSA_TX said:Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.
Regarding compounded supply compounding legality: compounding pharmacies can legally produce semaglutide and tirzepatide while these drugs remain on the FDA shortage list. If/when the shortage resolves, the legal landscape may change.
Stay informed. The FDA shortage list is updated regularly. Current status as of my last check: semaglutide shortage ongoing, tirzepatide partially resolved. This directly impacts compounding availability.
Moderator note: good thread. Keeping it here rather than moving it, because the question is general enough to be useful. Tagging this one for the weekly digest.